Bausch Health Companies Inc. (BHC) 2004 Q1 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning. My name is Jenny, and I will be your conference facilitator today. At this time, I would like to welcome everyone to Valeant Pharmaceuticals International first quarter 2004 conference call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer period. Please limit yourself to one question at a time to allow all participants an opportunity to ask questions. As a reminder, this call is being recorded. At this time for opening remarks and introductions, I would now like to turn the call over to Mr. Jeff Misakian, Vice President of Investor Relations.

    早安。我叫 Jenny,今天將擔任本次會議的主持人。此刻,我謹代表主辦方歡迎各位參加 Valeant Pharmaceuticals International 2004 年第一季電話法說會。為避免背景雜音干擾,所有線路已設為靜音。在講者致詞後,將進行問答時間。為讓所有與會者都有機會提問,請每次僅提一個問題。提醒各位,本通話將被錄音。接下來進行開場致詞與介紹,我現在把電話交給投資人關係副總裁 Jeff Misakian 先生。

  • Jeff Misakian - VP, Investor Relations

    Jeff Misakian - VP, Investor Relations

  • Thank you and good morning everyone and welcome to Valeant's first quarter 2004 earnings call. Before we begin, I'd like to call your attention to the fact that this presentation may contain forward-looking statements that involve risks and uncertainties, including but not limited to, projections of future sales, royalty income, operating income, returns on invested assets, regulatory approval processes, competition from generic products, marketplace acceptance of the Company's products, success of the Company's strategic repositioning initiatives and the ability of management to execute them, cost-cutting measures, success of the Company's strategic plan and the ability to achieve financial targets and cost reduction goals and other risks detailed from time to time in Valeant's SEC filings. These statements are based on current management's current expectations and involve risks and uncertainties that include Valeant's ability to retain key employees and reduce costs, general economic factors and business and capital market conditions, general industry trends and changes in tax all requirements and government regulation. Valeant wishes to caution the reader that these factors, as well as other factors described in Valeant's SEC filings, are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements.

    謝謝,各位早安,歡迎參加 Valeant 2004 年第一季財報電話會議。在開始之前,我想提醒各位,本簡報可能包含前瞻性陳述,涉及風險與不確定性,包括但不限於:未來銷售、權利金收入、營業利益、投資資產報酬、法規核准流程、學名藥競爭、市場對本公司產品的接受度、本公司策略性重新定位措施的成功與管理階層執行能力、成本削減措施、策略計畫的成功,以及達成財務目標與成本降低目標的能力,及 Valeant 不時於向 SEC 申報文件中所詳述的其他風險。上述陳述係基於管理階層目前的預期,並涉及風險與不確定性,其中包括 Valeant 留任關鍵員工與降低成本的能力、一般經濟因素與商業及資本市場狀況、產業整體趨勢,以及稅務要求與政府法規之變動。Valeant 提醒讀者注意,這些因素以及 Valeant 於 SEC 申報文件中所描述的其他因素,均可能導致實際結果與前瞻性陳述中所述預期出現重大差異。

  • Joining us on the call today are Robert W. O'Leary, Valeant's Chairman and Chief Executive Officer; Timothy C. Tyson, President and Chief Operating Officer; Bary G. Bailey, Executive Vice President and Chief Financial Officer and Kim D. Lamon, M.D., PhD., President and Chief Scientific officer. Wes Wheeler, President of North America and Global Commercial Development; Winnie Wu, Controller and Phil Lowber (ph), Treasurer, are also here and available to answer questions during the Q&A session. And now I would now like to turn the call over to Mr. O'Leary.

    今天與會者包括 Valeant 董事長兼執行長 Robert W. O'Leary;總裁兼營運長 Timothy C. Tyson;執行副總裁兼財務長 Bary G. Bailey,以及總裁兼首席科學長 Kim D. Lamon 醫師、博士。北美總裁暨全球商業發展總裁 Wes Wheeler;主計長 Winnie Wu,以及財務主管(ph)Phil Lowber 也在現場,並將於問答時段提供回答。現在我把電話交給 O'Leary 先生。

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • Thank you, Jeff, and thank you everyone for joining us this morning. This morning, we reported our first quarter results, which after excluding a charge for in-process research and development from our recent acquisition of Amarin shows a loss from continuing operations of $3.3 million, or 4 cents per diluted share. The loss reflects the ongoing investment in our research and development activities, manufacturing operations and our global products that we have been speaking to you about for sometime now, as well as a 48 percent decline in Ribavirin royalties. We have shown growth in our pharmaceutical business, which experienced a 20 percent increase in sales and an expansion in gross margin over last year's first quarter. While sales growth was aided by a favorable impact from foreign currency and lower sales in North America in 2003, we still saw improvements in nearly every region.

    謝謝你,Jeff,也謝謝各位今天早上加入我們。今天早上我們公布了第一季業績;若排除近期收購 Amarin 所產生的在研研發(in-process R&D)費用,我們持續營運的虧損為 330 萬美元,或稀釋後每股虧損 4 美分。該虧損反映了我們持續投入研發活動、製造營運,以及我們先前已多次向各位說明的全球產品,同時也反映 Ribavirin 權利金下滑 48%。我們的製藥業務呈現成長,銷售額較去年第一季增加 20%,且毛利率亦較去年第一季擴大。雖然銷售成長受惠於外幣匯率的有利影響,以及 2003 年北美銷售較低的基期因素,但我們在幾乎每個地區仍看到改善。

  • Although we saw an increase in product sales, it was not enough to close the revenue gap crated by the significant decline in Ribavirin royalties. Frankly, this was not unexpected. We anticipated limited royalty revenues from the U.S. market this year, primarily because of decreased sales of Rebetol by Schering-Plough and expected generic competition. However, as we have said many times, our focus is not on short-term earnings gains, but on long-term sustainable growth.

    儘管產品銷售增加,但仍不足以彌補 Ribavirin 權利金大幅下滑所造成的營收缺口。坦白說,這並不令人意外。我們預期今年來自美國市場的權利金收入有限,主要原因是 Schering-Plough 的 Rebetol 銷售下滑,以及預期的學名藥競爭。然而,正如我們多次強調的,我們的重點不在短期獲利提升,而在長期且可持續的成長。

  • To that important end, we remain on track to achieve our 2008 targets as well as our 2004 metric guidance. As a result of recent AMDA approval, Three Rivers and Sandoz launched generic versions of Ribavirin in early April and Schering launched its own generic immediately thereafter. The launch of generic Ribavirin will result in a significant decline in the royalty revenues in the United States, but this decline will have no impact on our ability to execute our strategic initiatives or fund our accelerated research and development efforts. We have a strong cash flow generation capability in our specialty pharmaceutical business and we will continue to receive royalties from international sales of Ribavirin as we have discussed before.

    為達成這一重要目標,我們仍按計畫推進,以達成 2008 年目標以及 2004 年的指標指引。由於近期 AMDA 核准,Three Rivers 與 Sandoz 於 4 月初推出 Ribavirin 的學名藥版本,Schering 隨後也立即推出自有學名藥。Ribavirin 學名藥上市將導致美國權利金收入顯著下滑,但此下滑不會影響我們執行策略性計畫或為加速研發投入提供資金的能力。我們的專科製藥業務具備強勁的現金流創造能力,且如先前所述,我們仍將持續自 Ribavirin 的國際銷售中取得權利金。

  • Our focus remains squarely on the business we can control. Our strategic decision to invest in our business is building a platform for future growth. These investments have been primarily directed toward our research and development activities, principally to fund our clinical trials for Viramidine and Remofovir our operations to further our lean Six Sigma efficiency efforts and our global manufacturing rationalization plan.

    我們的重點仍然完全放在我們可控的業務上。我們投資業務的策略性決策,正在建立未來成長的平台。這些投資主要投入於研發活動,尤其是為 Viramidine 與 Remofovir 的臨床試驗提供資金;同時也投入於營運,以推進精實六標準差(Lean Six Sigma)效率提升工作,以及我們的全球製造整併合理化計畫。

  • We have also increased our selling efforts in the first quarter to drive growth in our global products. In the meantime, we continue to maintain strict control over overhead costs as evidenced by the 22 percent decrease in general and administrative expenses this period compared to the same period last year.

    我們也在第一季加大銷售推動力道,以帶動全球產品成長。同時,我們持續嚴格控管間接費用;本期一般及行政費用較去年同期下降 22%,即為明證。

  • On the R&D front, you have seen a number of very positive headlines from Valeant. We presented 24-week clinical data from Phase II trials for Viramidine and the Phase I PK data for Remofovir at the European Association for the Study of the Liver, or EASL Conference, in April, which Tim will speak to shortly. We also have a number of line extension projects in the works which we plan to launch later in 2004.

    在研發方面,各位已看到 Valeant 多項非常正面的新聞標題。我們於 4 月在歐洲肝臟研究學會(European Association for the Study of the Liver,EASL)年會上,發表 Viramidine 第二期試驗的 24 週臨床數據,以及 Remofovir 的第一期藥物動力學(PK)數據,Tim 稍後將進一步說明。我們也有多個產品線延伸(line extension)專案正在進行中,計畫於 2004 年稍晚推出。

  • With that introduction, it is my pleasure to turn the call over to my colleague Tim Tyson, who will share more about the specialty pharmaceutical business and the operational improvements we've implemented throughout the organization. Tim?

    有了以上開場,我很高興把電話交給我的同事 Tim Tyson,他將分享更多關於專科製藥業務,以及我們在全組織推動並落實的營運改善。Tim?

  • Timothy Tyson - Co-President, COO

    Timothy Tyson - Co-President, COO

  • Thank you, Rob, and good morning everyone. The we continue to focus on accelerating our research and development programs, growing our specialty pharmaceutical business, investing in our core products and operations and identifying strategic acquisitions to accelerate growth in our business. The long-term future success of our business lies in the investing in activities that will drive the top line and allow us to implement an innovative strategy that will bring new products to market and fully capitalize on our global brand. The investments we have made in the last quarter will allow us to do just this. To drive the top line, we are aggressively pursuing opportunities to expand our product portfolio through internal discoveries and strategic acquisitions. You can begin to see this strategy unfolding through the step-by-step process we have followed to build our neurology platform recently.

    謝謝你,Rob,各位早安。我們將持續專注於加速研發計畫、擴大專科製藥業務、投資核心產品與營運,並尋找策略性併購以加速業務成長。我們業務長期成功的關鍵,在於投資能推動營收成長的活動,並使我們得以落實創新策略,將新產品推向市場,並充分發揮我們的全球品牌價值。我們在上一季所做的投資,將使我們能夠做到這一點。為推動營收成長,我們正積極尋求機會,透過內部研發成果與策略性併購擴充產品組合。透過我們近期為建立神經科平台所採取的循序漸進流程,各位已可開始看到此一策略逐步展開。

  • Long a core strength of the Company through our enduring Mestinon brand, we have begun to leverage our neurology capability through strategic acquisitions. We made our first such acquisition this quarter with the purchase of Amarin Pharmaceuticals and all of its U.S. products, including Permax, an adjunctive treatment for Parkinson's disease and the rights to Zelepar, an in-licensed late-stage candidate, also for the treatment of Parkinson's disease. Zelepar has received an approvable letter from the FDA subject to the completion of two safety studies which Amarin will fund. We expect to launch this product into the marketplace in 2005. The Phase III study results for Zelepar were published in the April edition of Movement Disorders.

    Mestinon 品牌長期以來一直是本公司的核心優勢之一,憑藉此一持久的品牌基礎,我們已開始透過策略性併購來發揮我們在神經科領域的能力。本季我們完成了第一宗此類併購,收購 Amarin Pharmaceuticals 及其所有美國產品,包括 Permax(用於帕金森氏症的輔助治療),以及 Zelepar 的權利(授權引進的後期研發候選藥物,同樣用於治療帕金森氏症)。Zelepar 已收到 FDA 的可核准函(approvable letter),惟須完成兩項安全性研究;該等研究將由 Amarin 出資。我們預期於 2005 年將此產品推向市場。Zelepar 的第三期(Phase III)研究結果已刊登於《Movement Disorders》四月號。

  • We have further built our neurology platform through today's announcement of the acquisition of rights to Tasmar in the United States and certain non-European union markets where it is currently sold. We acquired Tasmar from F. Hoffman-La Roche for $13.5 million in cash, plus royalties. Tasmar is an important therapeutic agent for patients suffering from severe Parkinson's disease and has patent protection through 2012. We expect this acquisition to be neutral to earnings in 2004. Under the terms of the agreement, Valeant Pharmaceuticals acquired the rights to manufacture, market and distribute Tasmar in these countries. Manufacturing of the product will transition to Valeant over the next two years. Peak sales of this product could approach $50 million within the next five years. These two acquisitions create a strong position in the Parkinson's area as we now have a trained neurology sales force, relationships with key opinion leaders, two marketed products and a follow-on medicine, Zelepar, expected to be available early next year. In the critical U.S. market, we will be able to leverage our newly built sales for his to sell these products, along with Mestinon, which historically had not received the promotional attention this life-saving therapy deserves.

    我們亦透過今日宣布收購 Tasmar 在美國及若干非歐盟市場(目前已在該等市場銷售)的權利,進一步建構我們的神經科平台。我們以 1,350 萬美元現金(另加權利金)自羅氏(F. Hoffman-La Roche)取得 Tasmar。Tasmar 對於罹患重度帕金森氏症的病患而言是一項重要的治療藥物,並享有專利保護至 2012 年。我們預期此項收購對 2004 年盈餘影響為中性。依協議條款,Valeant Pharmaceuticals 取得在上述國家製造、行銷及配送 Tasmar 的權利。該產品的製造將於未來兩年內逐步移轉至 Valeant。此產品在未來五年內的銷售高峰可能接近 5,000 萬美元。這兩項收購使我們在帕金森領域建立強勢地位:我們目前擁有受過訓練的神經科銷售團隊、與關鍵意見領袖的關係、兩項已上市產品,以及預期於明年初可取得的後續藥物 Zelepar。在關鍵的美國市場,我們將能運用新建立的銷售團隊來銷售這些產品,並同時推廣 Mestinon;歷史上,這項救命療法未曾獲得其應有的行銷關注。

  • During the quarter, our regions turned in good overall product performance, driven primarily by a significant increase in sales of our global brands, driving a 20 percent increase in overall specialty pharmaceutical sales. Sales in North America increased 80 percent to $27.6 million in the first quarter of 2004, compared to the same period last year. We have continued to maintain U.S. inventory at or below industry norms. Operating income in North America was $6.9 million, compared to an operating loss of $2.9 million in the same quarter of 2003. Gross margin for North America was 85 percent in the first quarter of 2004, up from 63 percent a year ago. The improvement in North America was primarily due to increased sales of Efudex, due to stronger demand in the first quarter and reduced sales in the 2003 first quarter due to the Company's wholesale inventory reduction measures.

    本季各區域整體產品表現良好,主要受全球品牌銷售大幅成長所帶動,使整體專科藥品銷售成長 20%。2004 年第一季北美銷售額較去年同期成長 80% 至 2,760 萬美元。我們持續將美國庫存維持在或低於產業常態水準。北美營業利益為 690 萬美元,相較 2003 年同季營業損失 290 萬美元。2004 年第一季北美毛利率為 85%,高於一年前的 63%。北美改善主要來自 Efudex 銷售增加:第一季需求較強,且 2003 年第一季因公司採取批發通路庫存去化措施而導致銷售較低。

  • In addition, the Company experienced increased demand for several products in the quarter, including Kinerase. Mestinon sales in North America were down as expected compared to last year due to generic competition in the United States. According to IMS prescription data, the Mestinon market share in the U.S. has stabilized at about 50 percent due to the strength of the brand, our promotional efforts and our affiliation with the Myasthenia Gravis Foundation. We've taken a number of steps in the past few months to strengthen our North American business, including price increases that are in line with industry trends, increased sales through the direct to physician channels, royalties from supply agreements and direct sales to government. Sales in Europe were 14 percent higher in 2004 first quarter, totaling $63.1 million compared to $55.6 million in the same quarter last year. The sales improvement includes a $6.2 million benefit from currency translation.

    此外,本季公司多項產品需求增加,包括 Kinerase。由於美國學名藥競爭,北美 Mestinon 銷售如預期較去年下滑。根據 IMS 處方資料,受惠於品牌力、我們的推廣努力,以及與重症肌無力基金會(Myasthenia Gravis Foundation)的合作關係,Mestinon 在美國的市占率已穩定在約 50%。過去數月我們採取多項措施以強化北美業務,包括符合產業趨勢的調價、透過直達醫師通路增加銷售、供應協議的權利金收入,以及對政府的直接銷售。2004 年第一季歐洲銷售額較去年同期成長 14%,達 6,310 萬美元(去年同季為 5,560 萬美元)。銷售改善包含匯率換算帶來的 620 萬美元利益。

  • Operating income in Europe was 21 percent higher in the first quarter of 2004, totaling $8.6 million compared to $7.1 million a year ago. Results in Europe were driven by an increase in sales of Mestinon and the successful launch of Dermatix. In Latin America, sales increased by 11 percent compared to the year ago period, while operating income was $1 million lower. Latin America absorbed severance costs as we continued to rebuild our leadership team in the region.

    2004 年第一季歐洲營業利益較去年同期成長 21%,達 860 萬美元(去年為 710 萬美元)。歐洲表現主要由 Mestinon 銷售增加及 Dermatix 成功上市所帶動。拉丁美洲銷售額較去年同期成長 11%,但營業利益減少 100 萬美元。拉丁美洲承擔了資遣費用,因我們持續重建該區域的領導團隊。

  • In 2004, we will continue to focus our greatest attention on growing our global brands, which increased significantly in the first quarter. The acquisition of Amarin Pharmaceuticals included a strong and experienced neurology sales force to manage and grow our neurology platform in the US. We recently launched Kinerase in our first European market and expect to add new markets in Europe very soon. We're also planning additional Kinerase line extensions in the U.S. this summer. We continue the launch of Dermatix throughout Europe and plan to launch Dermatix in the United States later this year. In addition, we have a number of line extensions in development for Mestinon and Efudex. We remain confident that these activities will enable our existing specialty pharmaceuticals business to achieve an industry level growth of 5-10 percent which will be accelerated through acquisitions. We continue to be active in the business development area and have numerous product acquisitions under review. We continue to be confident that we will have additional successes in this area in the months ahead.

    在 2004 年,我們將持續把最大重點放在推動全球品牌成長;這些品牌在第一季已顯著增加。收購 Amarin Pharmaceuticals 亦包含一支強而有經驗的神經科銷售團隊,用以在美國管理並擴展我們的神經科平台。我們近期已在歐洲第一個市場推出 Kinerase,並預期很快在歐洲新增更多市場。我們也規劃於今年夏季在美國推出更多 Kinerase 產品線延伸。我們持續在全歐洲推動 Dermatix 上市,並計畫於今年稍晚在美國推出 Dermatix。此外,我們亦有多項 Mestinon 與 Efudex 的產品線延伸正在開發中。我們仍有信心,這些活動將使我們既有的專科藥品業務達成 5%–10% 的產業水準成長,並將透過併購進一步加速。我們在業務開發方面仍相當積極,並正審視多項產品併購案。我們持續有信心在未來數月內將在此領域取得更多成果。

  • On the operations front, our global manufacturing initiative is progressing well with early benefit in efficiency improvement and procurement excellence, being offset by implementation expenses. Network rationalization activities are progressing well as we are preparing for significant product transfer. There has been significant interest generated in many of our manufacturing sites which may result in early sales of a number of the sites identified to be rationalized. As mentioned before, this is a 24-36 month process overall and we will share progress with you as we continue to execute on these plans. We had a number of achievements in our research and development activities with quarter and are extremely pleased with the progress being made by our scientists. Our rate of R&D spend of $18.5 million this quarter reflects the accelerated investments that we previously communicated for Phase III trials for Viramidine and investments in Remofovir. I've asked Dr. Kim Lamon to share with you some detailed information about our R&D activities this quarter.

    在營運方面,我們的全球製造倡議進展順利,效率提升與採購卓越所帶來的早期效益,正被導入(實施)費用所抵銷。隨著我們為重大產品移轉做準備,產能/據點網路合理化(network rationalization)工作亦進展良好。我們多個製造據點引發高度興趣,可能促成對若干已列入合理化名單之據點的提前出售。如先前所述,整體而言這是一個 24–36 個月的流程;在我們持續執行這些計畫的同時,也會與各位分享進度。本季我們在研發活動方面達成多項成果,並對科學家所取得的進展感到非常滿意。本季研發支出為 1,850 萬美元,反映我們先前已溝通之加速投資:包括 Viramidine 第三期試驗,以及對 Remofovir 的投資。我已請 Kim Lamon 醫師與各位分享本季研發活動的部分詳細資訊。

  • Kim Lamon - Co-President, CSO

    Kim Lamon - Co-President, CSO

  • Thank you, Tim. This has been a very, very busy quarter for our R&D development team and it doesn't look to slow down anytime soon. Let me first review the status of our ongoing Viramidine Phase II study.

    謝謝你,Tim。這一季對我們的研發團隊而言非常、非常忙碌,而且短期內看起來也不會放緩。我先回顧我們正在進行的 Viramidine 第二期(Phase II)研究進度。

  • We presented 24-week clinical data for Phase II of Viramidine at EASL in April and received extremely positive feedback from the physicians and scientists there. The data show that Viramidine demonstrates antiviral activity comparable to that of Ribavirin, but with a statistically significant lower incidence of anemia. This was a milestone of (indiscernible). It represents the first time clinical efficacy data for Viramidine has been presented as a major international medical conference. The data was presented by Dr. Robert Gish (ph), the lead investigator on the Phase II study and Medical Director of the Liver Transplant Program at California Pacific Medical Center in San Francisco. Dr. Gish is considered one of the pre-eminent hepetologists in the world. The reaction to the data presented at EASL adds further to our excitement for Viramidine's future in the hepatitis C market.

    我們在四月於 EASL 發表了 Viramidine 第二期的 24 週臨床數據,並獲得與會醫師與科學家極為正面的回饋。數據顯示,Viramidine 的抗病毒活性可與 Ribavirin 相當,但貧血發生率在統計上顯著較低。這是(聽不清)的里程碑。這代表 Viramidine 的臨床療效數據首次在主要國際醫學會議上發表。該數據由 Robert Gish 醫師(音)發表,他是第二期研究的主要研究者,亦為舊金山加州太平洋醫療中心肝臟移植計畫的醫療主任。Gish 醫師被視為全球最傑出的肝臟科醫師之一。EASL 對所發表數據的反應,進一步增添我們對 Viramidine 未來在 C 型肝炎市場前景的期待。

  • On May 18th, we will be presenting additional data from the Phase II trial at the Digestive Disease Week Conference in New Orleans and we plan to submit 48-week data from the study plus, additional safety data for the Phase II trial to the American Association for the Study of Liver Diseases, or AAFLD, for presentations this fall.

    5 月 18 日,我們將在紐奧良的 Digestive Disease Week Conference 發表第二期試驗的更多數據;此外,我們也計畫向美國肝病研究學會(American Association for the Study of Liver Diseases,或 AAFLD)提交該研究的 48 週數據以及第二期試驗的額外安全性數據,以供今年秋季發表。

  • Regarding our Phase III activity enrollment into our first trial, Pfizer I is progressing very well with the majority of sites up and actively enrolling patients. In addition, we have identified the via telephone pre-screening sufficient specific patients to fully enroll in this trial. We expect to kick off the second Phase III trial, Pfizer II, in the very near future.

    關於我們第三期的進展,第一項試驗 Pfizer I 的收案進度非常順利,多數試驗中心已啟動並積極收納病患。此外,我們已透過電話預篩選辨識出足夠的特定病患,可使本試驗達到完整收案。我們預期將在不久的將來啟動第二項第三期試驗 Pfizer II。

  • Our second clinical candidate, Remofovir, is being developed for hepatitis B. We recently completed a successful end of Phase I meeting with the FDA and have come to agreement on our Phase II protocol design. We're nearly completed with Phase I testing of Remofovir and expect to move into Phase II testing in mid-2004.

    我們的第二個臨床候選藥物 Remofovir 正在開發用於 B 型肝炎。我們近期與 FDA 成功完成第一期結束會議,並就第二期試驗方案設計達成共識。Remofovir 的第一期測試已接近完成,並預期於 2004 年年中進入第二期測試。

  • Regarding Zelepar, the results of the Phase III double-blind placebo-controlled trial of once-daily doses of Zelepar in the treatment of Parkinson's disease recently were published in the peer review journal Movement Disorder. In that study, Zelepar at 1.25 milligrams per day reduced off time by 2.2 hours, compared with only 0.6 hours for patients treated with placebo. Off time is a standard measure of a drug's effectiveness in Parkinson's disease.

    關於 Zelepar,近期每日一次劑量 Zelepar 治療帕金森氏症的第三期雙盲安慰劑對照試驗結果,已刊登於同儕審查期刊《Movement Disorder》。在該研究中,Zelepar 每日 1.25 毫克可將「off time」減少 2.2 小時,而安慰劑治療病患僅減少 0.6 小時。「off time」是衡量帕金森氏症藥物療效的標準指標。

  • As Tim mentioned, Zelepar has an approval letter from the FDA and two safety studies to complete the approval process of Zelepar are now in progress and we are expected to complete these studies (indiscernible) support approval and launch the product early next year.

    如 Tim 所提,Zelepar 已取得 FDA 的核准函,目前為完成 Zelepar 核准流程所需的兩項安全性研究正在進行中;我們預期完成這些研究(聽不清),以支持核准並於明年初推出產品。

  • Finally, we are all also working on a number of preclinical projects that we feel show promise in the areas of HIV, hepatitis C and hepatitis B. These projects are still in fairly early stages, but we plan to share more with you in the near future. Now I will turn the call over to Bary Bailey to discuss specifics regarding the financials.

    最後,我們也正投入多項臨床前專案,我們認為其在 HIV、C 型肝炎與 B 型肝炎領域具備潛力。這些專案仍處於相當早期階段,但我們計畫在不久的將來與各位分享更多資訊。現在我將把電話交給 Bary Bailey,討論財務方面的細節。

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • Thank you, Kim. Well, stating the obvious, our adjusted loss excluding the impact of in-process research and development in the first quarter of 4 cents per diluted share is below street expectations. There are two primary reasons for this difference. First, royalties from Schering and Roche were significantly lower than what most everyone was expecting. Second, although we previously indicated that selling expense would be proportionately higher in our first half of the year, such expenses were still more than what the market expected. I will address each of these areas in just a moment.

    謝謝你,Kim。嗯,顯而易見地,我們第一季在排除進行中研發(in-process research and development)影響後的調整後虧損為每股稀釋後 4 美分,低於市場預期。造成此差異主要有兩個原因。第一,來自 Schering 與 Roche 的權利金顯著低於多數人預期。第二,儘管我們先前指出上半年銷售費用占比會較高,但該等費用仍高於市場預期。我稍後將逐一說明這些領域。

  • Top line sales results are consistent with our expectations in the first quarter of 2004 with an increase of $22.2 million, or 20 percent over the same period last year. Excluding the impact of foreign currency, product sales were up 13 percent. As you may recall, sales in the first quarter last year were lower as a result of our wholesale inventory reduction efforts.

    2004 年第一季的營收(top line)表現符合我們預期,較去年同期增加 2,220 萬美元,或成長 20%。若排除外幣影響,產品銷售成長 13%。各位或許記得,去年第一季的銷售較低,係因我們進行通路庫存(wholesale inventory)降低的努力所致。

  • As noted above and as you can see on table 6 of our release, foreign currency continues to benefit us on the top line. But as before, the impact to operating income is substantially less with a company-wide net impact to operating income of only about $500,000. That said, the Company has entered into foreign currency hedge agreements covering approximately EUR22 million in 2004 to reduce our overall exposure to currency fluctuations, and we will continue to look at other opportunities to mitigate the fluctuations in this area.

    如上所述,且如各位在我們新聞稿的表 6 所見,外幣持續在營收端對我們有利。但與先前相同,對營業利益的影響小得多;全公司層面對營業利益的淨影響僅約 50 萬美元。即便如此,公司已簽訂外匯避險合約,涵蓋 2004 年約 2,200 萬歐元,以降低整體匯率波動曝險;我們也將持續尋找其他機會,以緩解此領域的波動。

  • Royalty revenues declined 48 percent in the first quarter $25.4 million, reflecting lower Rebetol sales by Schering-Plough as a result of Schering's post inventory issues and increased market competition. We also received royalties for Roche on worldwide sales of Copegus in the quarter, but at a lower rate than those paid by Schering. As a reminder, because of the recent generic Ribavirin launch, gross royalties ceased in any market with generic competition. So Roche will no longer pay us royalties for Copegus sales in the U.S. market.

    第一季權利金收入下降 48% 至 2,540 萬美元,反映 Schering-Plough 因 Schering 的後續庫存問題以及市場競爭加劇,導致 Rebetol 銷售下滑。本季我們也就 Roche 的 Copegus 全球銷售取得權利金,但其支付比率低於 Schering。提醒各位,由於近期學名藥 Ribavirin 上市,在任何存在學名藥競爭的市場,我們的總權利金(gross royalties)即停止。因此,Roche 將不再就美國市場的 Copegus 銷售向我們支付權利金。

  • Generic competition to Ribavirin will result in a substantial decline in U.S. royalties in the future and as a result of aggressive generic adoption, we expect total royalties in the second quarter to be somewhat less than what we have reported in the first quarter. We continue to expect royalty revenues from sales of Ribavirin overseas and approximately 70 percent of total royalties in the first quarter were from such sales of oral Ribavirin outside of the U.S.

    Ribavirin 的學名藥競爭將使未來美國權利金大幅下滑;且由於學名藥採用速度積極,我們預期第二季總權利金將略低於第一季所報告的水準。我們仍預期可自海外 Ribavirin 銷售取得權利金;第一季總權利金中約 70% 來自美國以外的口服 Ribavirin 銷售。

  • Overall, our gross margin in the first quarter increased to 65 percent from 63 percent in the same period last year. The increase was primarily due to a change in geographic mix with increased contributions from North America. The gross margin remained stable in the first quarter, is on track with our 2004 metric guidance.

    整體而言,我們第一季毛利率由去年同期的 63% 提升至 65%。此提升主要來自地理組合變化,北美地區貢獻增加。第一季毛利率維持穩定,符合我們 2004 年指標(metric)指引的進度。

  • We continue to make investments in our operations which results in an increase in cost of goods sold. As previously indicated, we have accelerated in depreciation expense associated with facilities that we expect to dispose of over the next couple of years. The impact of this acceleration is an increase in depreciation expense of $1.8 million, as compared to the same period in the prior year. To the extent that the sales of these facilities would occur sooner, this depreciation would be reduced but may be offset by potential losses on the sale.

    我們持續投資於營運,因而使銷貨成本增加。如先前所述,對於我們預期在未來幾年內處分的設施,我們已加速認列相關折舊費用。相較於前一年度同期,此加速的影響使折舊費用增加 180 萬美元。若這些設施能更早出售,折舊費用將降低,但可能會被出售時的潛在損失所抵銷。

  • In addition, we continue to invest in our operational efficiency efforts, but this is being offset in the course of the year by resulting improvement. Selling expenses were up 28 percent in the first quarter of 2004 compared to same period last year. The increase reflects investments in our core business which we discussed with you last quarter, as well as an impact from foreign currency translation. In fact, we specifically said that selling expense would be higher in the first half of 2004 than in the latter half due to the timing of these expenditures. We are investing in marketing for our global brand to support the key initiatives discussed earlier by Tim. While higher this quarter, we expect selling expense in 2004 to be in the range of our previous guidance of 30-32 percent of sales.

    此外,我們持續投資於提升營運效率的工作,但在年度進程中,這些投入將被隨之而來的改善所部分抵銷。2004 年第一季銷售費用較去年同期增加 28%。此增幅反映我們對核心業務的投資(我們在上季已與各位討論),以及外幣換算的影響。事實上,我們曾明確表示,由於支出時點的關係,2004 年上半年的銷售費用將高於下半年。我們正投入全球品牌的行銷,以支持 Tim 先前提到的關鍵倡議。雖然本季較高,但我們預期 2004 年銷售費用將落在先前指引的區間,即占銷售額的 30% 至 32%。

  • We continue to make progress in reducing our G&A expense, which declined 22 percent in the 2004 first quarter to $23.9 million, compared to the same period last year, primarily due to lower legal fees. While we are pleased with this improvement, legal fees can and will fluctuate significantly from quarter to quarter. That being said, we remain comfortable with our guidance for G&A expense in 2004 of between 20 and 21 percent of sales.

    我們在降低一般及行政(G&A)費用方面持續取得進展;2004 年第一季的 G&A 費用較去年同期下降 22%,至 2,390 萬美元,主要是因為法律費用降低。雖然我們對此改善感到滿意,但法律費用可能且確實會在各季度之間大幅波動。即便如此,我們仍對 2004 年 G&A 費用指引(占銷售額 20% 至 21%)保持信心。

  • R&D expenses were up significantly in the 2004 first quarter due to Pfizer I trial enrollment for Viramidine and an initial investment in Phase II trials for Remofovir. Our continued progress in 2004 in those trials will drive R&D expenses which we expect to fall in the range of between $85 and $95 million in 2004 as previously communicated. Amortization expense was 65 percent higher in the first quarter 2004 than in the same period last year due to our Ariva Pharm acquisition in the third quarter of 2003 and our most recent acquisition of Amarin, which had an amortization impact of approximately $500,000 for the quarter. We expect -- we continue to expect amortization expenses in 2004 to be in the range of between 50 and $55 million, but future acquisitions will likely increase this estimate.

    由於 Viramidine 的 Pfizer I 期試驗收案(入組)以及對 Remofovir II 期試驗的初始投入,2004 年第一季研發(R&D)費用大幅上升。我們在 2004 年於這些試驗上的持續進展將推動研發費用;如先前所溝通,我們預期 2004 年研發費用將落在 8,500 萬至 9,500 萬美元之間。由於我們於 2003 年第三季收購 Ariva Pharm,以及近期收購 Amarin(本季攤銷影響約 50 萬美元),2004 年第一季攤銷費用較去年同期高出 65%。我們預期——並持續預期——2004 年攤銷費用將介於 5,000 萬至 5,500 萬美元之間,但未來的收購很可能會提高此估計。

  • As a note, the Amarin acquisition had a negative impact of about $1 million pretax in the first quarter. About half of this was due to the amortization and the additional costs associated with addressing the business issues of the Company. We expect for the year that this will be neutral low.

    補充說明,Amarin 的收購在第一季對稅前造成約 100 萬美元的負面影響。其中約一半來自攤銷,以及處理該公司業務議題所產生的額外成本。我們預期就全年而言,這項影響將接近中性、略為偏低。

  • Interest expense was 63 percent higher the first quarter of 2004 versus the same period in 2003 as a result of the new debt issued late last year through our refinancing initiative and our continued carry of the 6.5 percent convertible subordinated note. This expense was partially offset by an increase of about $2.1 million in interest income due to our higher level of cash balances. We plan to regain the remaining $326 million and 6.5 percent convertible subordinated notes on or prior to the first redemption date in July, which will result in a pretax loss upon redemption of about $19 million. We continue to expect net interest expense in 2004 to be approximately $40 million. The Company's effective tax rate for continuing operations in the first quarter of 2004 was 37 percent. This is in line with our expectations for a 36-37 percent range in 2004. With that, I would now like to turn the call over to Rob for closing comments.

    由於我們在去年稍晚透過再融資計畫發行的新債,以及持續持有 6.5% 可轉換次順位票據,2004 年第一季利息費用較 2003 年同期高出 63%。此費用部分被利息收入增加約 210 萬美元所抵銷,主要因為我們的現金餘額水準較高。我們計畫在 7 月的首次贖回日當日或之前,買回剩餘 3.26 億美元、利率 6.5% 的可轉換次順位票據,這將導致贖回時約 1,900 萬美元的稅前損失。我們仍預期 2004 年淨利息費用約為 4,000 萬美元。公司 2004 年第一季持續營運的有效稅率為 37%。這與我們對 2004 年 36% 至 37% 區間的預期一致。接下來,我想把電話會議交給 Rob 作結語。

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • Thank you, Bary. The message you've heard this morning is one of consistence, focused investment in our core business and R&D activities that we believe will drive growth in the future. This is a message that we have been communicating consistently for the past 2-3 quarters and has clearly impacted our results in the first quarter of what is a foundation building year.

    謝謝你,Bary。各位今天早上聽到的訊息,是一致性、聚焦於核心業務的投資,以及我們相信將推動未來成長的研發活動。這是我們在過去 2 到 3 個季度持續傳達的訊息,並且已清楚反映在第一季的業績上;而今年是一個打基礎的年度。

  • We're truly excited about the progress made in our research and development activities, our global manufacturing initiatives and our continued growth of our global brands. We have made progress in our business development activities with two recent acquisitions in our Kinerase line extensions. More extensions and reformulations are planned and we continue to expect additional acquisitions during that this year. I am confident that these activities will result in the creation of a sustainable, long-term and profitable growth company.

    我們對研發活動的進展、全球製造計畫,以及全球品牌的持續成長感到非常振奮。在業務發展方面,我們近期完成兩項收購,用於我們 Kinerase 產品線的延伸。我們規劃更多延伸與重新配方,並且仍預期今年還會有額外收購。我有信心,這些活動將使我們打造一家可持續、長期且獲利成長的公司。

  • I want to remind you -- our cash position remains strong, our specialty pharmaceuticals business is growing and we're confident this business and our remaining royalties will continue to generate strong cash flow, even after the investments we're making in the lean Six Sigma and our manufacturing rationalization efforts. As we have indicated in the past, even with the challenge of royalties in the U.S., we believe royalties will be adequate to fund our current accelerated R&D efforts. We will continue to support our outstanding R&D team as they grow in their drug discovery and pre-clinical development capabilities and continue to invest in the development of Viramidine and Remofovir.

    我想提醒各位——我們的現金部位仍然強勁,我們的專科藥品業務正在成長,而且我們有信心,該業務與我們剩餘的權利金將持續產生強勁的現金流,即使在我們對精實六標準差(Lean Six Sigma)以及製造合理化(rationalization)工作的投資之後亦然。如同我們過去所指出,即便面臨美國權利金的挑戰,我們仍相信權利金足以支應我們目前加速的研發投入。我們將持續支持我們傑出的研發團隊,協助其提升藥物發現與臨床前開發能力,並持續投資 Viramidine 與 Remofovir 的開發。

  • Now, following the question and answer period which will begin momentarily, I will return to give you a brief update on our succession planning and our advancements in corporate governance. Thank you all for joining us today and now I would as the operator to give us the first question please.

    接下來,在即將開始的問答環節之後,我會回來向各位簡要更新我們的接班規劃,以及公司治理方面的進展。感謝各位今天加入我們;現在我想請接線員為我們安排第一個問題。

  • Operator

    Operator

  • (Operator Instructions). Michael Tong, Wachovia Securities.

    (接線員指示)。Wachovia Securities 的 Michael Tong。

  • Michael Tong - Analyst

    Michael Tong - Analyst

  • Thank you for taking the question. I have one for Bary and one for Tim. Bary, can you give us your CapEx and cash flow from operations number for the first quarter? And Tim, I noticed that the operating margins for North America and Latin America were down pretty significantly sequentially versus Q3 and Q4 of '03. Can you share some color on that, as well as how you think the operating margins for those geographic areas will trend as we look out to the rest of '04?

    謝謝讓我提問。我有一個問題要問 Bary,另一個要問 Tim。Bary,你能提供第一季的資本支出(CapEx)以及營運活動現金流的數字嗎?另外 Tim,我注意到北美與拉丁美洲的營業利益率相較於 2003 年第三季與第四季,按季下滑相當明顯。你能否補充一些背景說明,以及你認為在展望 2004 年剩餘期間時,這些地區的營業利益率走勢會如何?

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • Michael, good morning. You managed to get in a number of questions there. We're going to handle them this way, if you don't mind. We're going to do CapEx with Barry and then Phil Lowber will handle the cash flow question and then we will turn to Tim for the Latin American question. Bary, you want to lead off please?

    Michael,早安。你一次問了不少問題。如果你不介意,我們會這樣處理。我們先由 Barry 回答資本支出(CapEx),接著由 Phil Lowber 回答現金流問題,然後再請 Tim 回答拉丁美洲的問題。Bary,你先開始好嗎?

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • Yes, Michael. First of all, relative to the cash flow issue, that will come out in the cash flow statements in the Q, which will be coming out shortly. We have not disclosed that separately here. But as far as CapEx in the first quarter, we had about $4 million. As you recall, we see our maintenance CapEx running at about $20 million per year. Tim?

    好的,Michael。首先,關於現金流的議題,相關數字會在即將發布的 Q(季報)中的現金流量表揭露。我們在這裡沒有另外單獨披露。至於第一季的資本支出(CapEx),約為 400 萬美元。如你所記得,我們的維護性資本支出大約是每年 2,000 萬美元。Tim?

  • Timothy Tyson - Co-President, COO

    Timothy Tyson - Co-President, COO

  • Thank you, Michael, for your question and I appreciate your support. The operating incomes in Latin America first are due to some changes of the leadership team there that I mentioned earlier and some costs that we paid off for severances. We continue to have a focus down in Latin America that will drive the business. Some one-off costs affected us there and a focus on appropriate global products will have -- and make a difference there. In North America, we have been investing in a number of things as we have told you, and those investments are starting to pay off and those investments have affected the operating margins. But we are confident that we will deliver on the metrics that we have given you from a consolidated standpoint and you will see improvements in all regions.

    Michael,謝謝你的提問,也感謝你的支持。拉丁美洲的營業利益首先是因為我先前提到的當地領導團隊變動,以及我們支付的一些遣散費成本。我們在拉丁美洲仍然保持聚焦,以推動業務發展。一些一次性成本在當地影響了我們,而聚焦於合適的全球產品將會——並且會在那裡帶來改變。在北美方面,如同我們告訴各位的,我們在多個領域進行投資,這些投資開始產生回報,但也影響了營業利益率。不過,我們有信心能在合併層面達成我們提供的各項指標,你也將看到所有地區的改善。

  • Michael Tong - Analyst

    Michael Tong - Analyst

  • Okay.

    好的。

  • Operator

    Operator

  • Larry Smith, DLS Research.

    Larry Smith,DLS Research。

  • Larry Smith - Analyst

    Larry Smith - Analyst

  • If I could sneak in two questions. One is very quick. I think I'm following most of your guidance and I get about a breakeven year for this year, in terms of earnings-per-share. I do not recall that you have ever given any guidance on earnings-per-share, but does that sound about reasonable? And then the second question I have is on the clinical development of Viramidine. Should we anticipate that the registration or filing strategy will await the completion of Pfizer II, and then with the time required to compile the data and submit it to the FDA and have the FDA act? Or, is there a quicker filing strategy where you might file off of the 48-week Phase II data, along with Pfizer I, which could possibly accelerate the NDA approval by some period of time? I don't think I worded that very well, but I think you know what I'm trying to get at.

    如果我可以再插入兩個問題。第一個很快。我想我大致理解你們大部分的指引,按每股盈餘來看,我算出今年大約是損益兩平的一年。我不記得你們曾經對每股盈餘提供過任何指引,但這樣聽起來是否算合理?第二個問題是關於Viramidine的臨床開發。我們是否應該預期註冊或申報策略會等到Pfizer II完成之後,再加上彙整資料、提交給FDA並等待FDA審查所需的時間?或者,是否有更快的申報策略,例如以48週的第二期數據加上Pfizer I來申報,可能在某種程度上加速NDA核准?我覺得我表達得不太好,但我想你知道我想問的是什麼。

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • Good morning, Larry. Dr. Kim Lamon will deal with the question. Let me first respond to the earnings guidance question. Your memory is absolutely correct. We have not provided earnings guidance. However, we have provided metrics for 2004 and we believe that our guidance relative to those metrics is unchanged. And of course, Larry, you know I cannot speculate on your conclusions. Let me turn things over to Kim to answer about the question on Viramidine.

    早安,Larry。這個問題將由Kim Lamon醫師來處理。我先回應每股盈餘指引的問題。你的記憶完全正確。我們沒有提供每股盈餘的指引。不過,我們已提供2004年的一些衡量指標,我們認為相對於這些指標的指引並未改變。當然,Larry,你也知道我不能對你的結論做任何推測。我把時間交給Kim來回答關於Viramidine的問題。

  • Kim Lamon - Co-President, CSO

    Kim Lamon - Co-President, CSO

  • Hi, Larry. Yes, I do know what you're getting at. Right now, the development plan is something I call here Viramidine Classic, which is the Phase II study and two pivotal studies. If you map that out, we have said previously that we are still comfortable with an expectation of a launch in '07. That being said, there are three things that can really impact the registration strategy. One is obviously enrollment, two is how quickly at the completion of the study we can get things wrapped up and summarized, and three is the strength of the data. So I think it's very fair to say that while we have Viramidine Classic out there, there are four or five other strategies, including the one you mentioned, that we are thinking about. But again, that strategy will be driven by the strength in the data.

    嗨,Larry。是的,我知道你想問什麼。目前的開發計畫,我在這裡稱之為Viramidine Classic,也就是一項第二期研究加上兩項關鍵性試驗。如果把時程攤開來看,我們先前說過,我們仍然有信心預期在07年上市。話雖如此,有三個因素會真正影響註冊策略。第一當然是收案進度,第二是在研究完成後我們能多快把事情收尾並完成彙整,第三是數據的強度。所以我認為可以很公平地說,雖然我們目前有Viramidine Classic這條路徑,但我們也在思考另外四、五種策略,包括你提到的那一種。但同樣地,策略將由數據的強度所驅動。

  • Larry Smith - Analyst

    Larry Smith - Analyst

  • Okay, thank you.

    好的,謝謝。

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • Thank you, Larry.

    謝謝你,Larry。

  • Operator

    Operator

  • Michael Tong, Wachovia Securities.

    Michael Tong,Wachovia Securities。

  • Michael Tong - Analyst

    Michael Tong - Analyst

  • Hi. If I could sneak one more back in. As far as your North American marketing organization, how large is that sales force right now and how large do you anticipate that will go to?

    嗨。如果我可以再插入一個問題。就你們北美行銷組織而言,目前銷售團隊規模有多大?你們預期會擴增到多大?

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • I'm going to turn that question to Wes Wheeler, who runs the North American operation.

    我把這個問題交給負責北美營運的Wes Wheeler。

  • We Wheeler. Michael, our current sales force, including the Amarin sales force that we just acquired is just at about 90. We expect to grow that up to about 114-115 as we get closer to the Zelepar launch.

    Wes Wheeler。Michael,我們目前的銷售團隊(包含我們剛收購的Amarin銷售團隊)大約是90人。我們預期在更接近Zelepar上市時,會成長到大約114到115人。

  • Michael Tong - Analyst

    Michael Tong - Analyst

  • Okay. And from a therapeutic category perspective, how do you separate them out, as far as derm, neurology is concerned?

    好的。從治療領域的角度來看,例如皮膚科、神經科,你們是如何區分配置的?

  • Wes Wheeler - Pres., North American & Global Mktg. & Bus. Development

    Wes Wheeler - Pres., North American & Global Mktg. & Bus. Development

  • We have 65 dermatology reps. They're full-time on the derms, about 5000 derms we call on a regular basis, and we have 24 currently in neurology and we will grow that to about 48 next year.

    我們有65位皮膚科業務代表。他們全職負責皮膚科,我們定期拜訪大約5,000位皮膚科醫師;目前神經科有24位,明年我們會擴增到大約48位。

  • Michael Tong - Analyst

    Michael Tong - Analyst

  • Great, thank you.

    很好,謝謝。

  • Operator

    Operator

  • (Operator Instructions).

    (接線員指示)。

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • I want to thank you. Is there another question?

    謝謝各位。還有其他問題嗎?

  • Operator

    Operator

  • Robert Uhl, Wells Fargo.

    Robert Uhl,Wells Fargo。

  • Robert Uhl - Analyst

    Robert Uhl - Analyst

  • Thank you. Can you just explain a little bit more on the Ribavirin royalty calculation? Has anything happened with the way the calculation is done off the Schering sales? And are they still paying the same royalty rate off their generic product that they pay off the brand?

    謝謝。你們能否再多解釋一下Ribavirin權利金的計算方式?以Schering的銷售額為基礎的計算方式有沒有發生任何變化?另外,他們對其學名藥產品支付的權利金比率,是否仍與品牌藥相同?

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • Robert, good morning, and I'm going to Bary Bailey, Our Chief Financial Officer, to respond to that.

    Robert,早安。我把這個問題交給我們的財務長Bary Bailey來回應。

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • Good morning, Robert. There is no change in the rate that they repay, regardless of whether they launch out of their generic business or whether they launch out of their branded business. As you recall, we have indicated that it goes up in tiers based on sales volume, but there is no change in that relative to whether it is generic or not.

    早安,Robert。無論他們是以學名藥業務推出,或是以品牌業務推出,支付的比率都沒有改變。如你所記得的,我們曾表示該比率會依銷售量採分級(tier)上調,但是否為學名藥並不影響這一點。

  • Robert Uhl - Analyst

    Robert Uhl - Analyst

  • Alright. And when you guys said that royalty stream funds R&D, that would imply that the royalty stream will be at least 85-95 million for this year?

    了解。那你們說權利金收入可支應研發,這是否意味著今年的權利金收入至少會有8,500萬到9,500萬美元?

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • Based on information and what we see, that is consistent.

    根據我們掌握的資訊以及我們所看到的情況,這樣的推估是一致的。

  • Operator

    Operator

  • (indiscernible), Mehta Partners.

    (聽不清楚),Mehta Partners。

  • Unidentified speaker

    Unidentified speaker

  • Hello, good morning gentlemen. I just have a quick question. I'm happy to see the Tasmar acquisition coming today, but wanted to get an update on your future acquisition plans for the rest of the year?

    各位先生早安。我只有一個簡短問題。很高興看到今天Tasmar收購案完成,但想請你們更新一下今年剩餘時間的未來收購計畫?

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • Tim Tyson will respond.

    Tim Tyson會回應。

  • Timothy Tyson - Co-President, COO

    Timothy Tyson - Co-President, COO

  • Thank you, Shoshone (ph). As we've communicated, we're actively out in the marketplace. We have a number of activities and projects that we are looking at, around 30, and we continue to expect to be successful in the coming months.

    謝謝你,Shoshone(音)。如同我們所溝通的,我們正積極在市場上尋找機會。我們正在評估多項活動與專案,大約30個,並且我們仍預期在未來幾個月能夠取得成果。

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • Thank you, next question, please.

    謝謝,請下一個問題。

  • Operator

    Operator

  • Rachel Golder, Goldman Sachs.

    Rachel Golder,Goldman Sachs。

  • Rachel Golder - Analyst

    Rachel Golder - Analyst

  • Good morning. Just so I can understand modeling Amarin in going forward, can you give us a sense of what their annual revenues and operating income was the entire year? And then any initiatives that you might have going forward that might change the basic balance of their contribution to you, like increase in sales force investments?

    早安。為了讓我能理解未來對Amarin的建模,你們能否提供他們全年年度營收與營業利益的大致數字?另外,未來是否有任何可能改變他們對你們貢獻基本結構的措施,例如增加銷售團隊投資?

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • Thank you, Rachel, and good morning and I will turn that over to Tim Tyson.

    謝謝你,Rachel,早安。我把這個問題交給Tim Tyson。

  • Timothy Tyson - Co-President, COO

    Timothy Tyson - Co-President, COO

  • Thank you for the question, Rachel. We had about $18 million in sales from Amarin last year. And going forward, we have a number of plans. I'm just going to ask Wes to comment quickly on some of the go-forward plans.

    謝謝你的問題,Rachel。去年我們來自Amarin的銷售額約為1,800萬美元。展望未來,我們有多項計畫。我請Wes快速評論一下部分後續計畫。

  • Wes Wheeler - Pres., North American & Global Mktg. & Bus. Development

    Wes Wheeler - Pres., North American & Global Mktg. & Bus. Development

  • Of course Amarin in the last year has been a little bit of an anomaly because of the Permax situation going off patent in 2003. So it's tough to kind of compare year-on-year. The current product line is made up of about five legacy products, which we consider primary care type products, plus Permax, and that does annualize at about $18 million a year. Of course, that will change significantly next year as we launch Zelepar.

    當然,Amarin 在過去一年有點屬於異常情況,因為 Permax 在 2003 年因專利到期的狀況所致。所以要做年度同比比較有點困難。目前的產品線大約由五個既有產品組成,我們把它們視為基層醫療類型產品,再加上 Permax;按年化計算約為每年 1,800 萬美元。當然,明年我們推出 Zelepar 後,這個數字將會顯著改變。

  • Rachel Golder - Analyst

    Rachel Golder - Analyst

  • How much of the 18 million of revenues was Premax last year?

    去年 1,800 萬美元的營收中,有多少是來自 Permax?

  • Wes Wheeler - Pres., North American & Global Mktg. & Bus. Development

    Wes Wheeler - Pres., North American & Global Mktg. & Bus. Development

  • On an annual scrip basis, I would give Permax 7-8 million of that, and about 10 million from the legacy products.

    以年度處方量(scrip)為基礎來看,我會說 Permax 佔其中的 700 萬到 800 萬美元,既有產品約 1,000 萬美元。

  • Rachel Golder - Analyst

    Rachel Golder - Analyst

  • And Permax going forward, since it's not now off patent, should we haircut that 7-8 by a significant portion?

    那麼 Permax 往後,既然現在已經不再有專利保護,我們是否應該把那 700 萬到 800 萬大幅打折?

  • Wes Wheeler - Pres., North American & Global Mktg. & Bus. Development

    Wes Wheeler - Pres., North American & Global Mktg. & Bus. Development

  • That's a good question. The way to answer that is look at our Mestinon performance. Permax fits the same sort of a mold. We're holding onto about 30 percent the molecule and we expect to hold that for the next 12 months.

    這是個好問題。回答方式是看我們 Mestinon 的表現。Permax 符合相同的模式。我們目前保住了該分子約 30% 的份額,並預期未來 12 個月也能維持。

  • Rachel Golder - Analyst

    Rachel Golder - Analyst

  • Great. Thank you very much.

    很好。非常感謝。

  • Operator

    Operator

  • Michael Sansky (ph), Tudor Investments.

    Michael Sansky(音),Tudor Investments。

  • Michael Sansky - Analyst

    Michael Sansky - Analyst

  • A number of questions, Bary. The other income item is a negative 1 million. I'm assuming there's 4 million of interest income in there. Is there a net $5 million number in there, and what is that?

    Bary,我有幾個問題。其他收入那一項是負 100 萬美元。我假設裡面有 400 萬美元的利息收入。那裡面是否有一個淨額負 500 萬美元的數字?那是什麼?

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • The other income is predominantly due to the fact that we got out of some investments that the prior management had made. The investments had been declining in value. But due to foreign currency translation, we were able to buy them out at the original investment amount. So for both purposes, it shows a loss, but we've put in $5 million into it and took 5 million out. And that is really what drove that loss in that line called translation and other; it is predominantly other.

    其他收入主要是因為我們退出了前任管理層所做的一些投資。那些投資的價值一直在下滑。但由於外幣換算的因素,我們得以用原始投資金額把它們買回/退出。所以從帳面角度看會顯示虧損,但我們投入了 500 萬美元,也取回了 500 萬美元。而這正是那條名為「換算及其他」(translation and other)的科目出現虧損的主因;其中主要是「其他」。

  • Michael Sansky - Analyst

    Michael Sansky - Analyst

  • So there's a $5 million negative net there.

    所以那裡面有淨額負 500 萬美元?

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • No, it's about $1 million negative hit. We put 5 million in the investment, old prior management did in U.S. dollars; we took out 5 million in U.S. dollars. But because over time you had fluctuations from foreign currency because it was treated as a long-term investment, it shows as a loss for book purposes. But for cash purposes, 5 million went in several years ago, 5 million came out. It was really a result of translation --.

    不,大約是負面影響 100 萬美元。我們在投資中投入 500 萬美元(前任管理層以美元投入);我們也以美元取回 500 萬美元。但因為隨時間推移,外幣匯率波動(由於被視為長期投資)會造成帳面上顯示虧損。但就現金而言,幾年前投入 500 萬美元,現在取回 500 萬美元。這其實是換算的結果——。

  • Timothy Tyson - Co-President, COO

    Timothy Tyson - Co-President, COO

  • It was all the translation in the different rates of the euro at the time the investments were made.

    完全是因為在投資進行時,歐元匯率在不同時間點的差異所造成的換算。

  • Michael Sansky - Analyst

    Michael Sansky - Analyst

  • So there is a $5 million net in that number?

    所以那個數字裡有淨額 500 萬美元?

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • No. There is no $5 million net hit. It is a $1 million hit.

    沒有。沒有淨額負 500 萬美元的影響。是負面影響 100 萬美元。

  • Michael Sansky - Analyst

    Michael Sansky - Analyst

  • You said that supply chain expenses are in the quarter. I'm assuming they were net negative. How should we think about those costs for the rest of the year?

    你提到本季有供應鏈費用。我假設它們淨額是負的。我們應該如何看待今年剩餘期間的這些成本?

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • You said supply chain what?

    你說供應鏈什麼?

  • Michael Sansky - Analyst

    Michael Sansky - Analyst

  • Your supply initiative, supply chain initiative manufacturing.

    你們的供應計畫、供應鏈計畫、製造方面。

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • I'm sorry -- what is your question, Michael?

    抱歉——你的問題是什麼,Michael?

  • Michael Sansky - Analyst

    Michael Sansky - Analyst

  • I think Tim said there were some costs in there that were borne. Can you give us a sense of how that looks going forward?

    我想 Tim 說裡面承擔了一些成本。你能否讓我們了解一下,往後會是什麼樣子?

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • The manufacturing initiative is progressing well. We have made investments in the launch of a lean Six Sigma program and we're doing the activities necessary to move products and to remove or reduce the number of facilities. So what you're seeing in this quarter is some of the investments. We're seeing some early benefit from our procurement initiative and from our lean Six Sigma activities, and that is being offset by the expenses for implementation. And going forward, we expect to see the benefits that we have communicated.

    製造改善計畫進展良好。我們已在精實六標準差(Lean Six Sigma)計畫的導入上進行投資,並在推動必要的活動,以移轉產品並移除或減少廠房數量。所以你在本季看到的是部分投資。我們從採購改善計畫以及精實六標準差活動中看到一些早期效益,但這些效益被導入/實施費用所抵銷。展望未來,我們預期會看到我們已對外溝通的效益。

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • In general, just to respond, Michael, of course you remember, we are reducing our 17 plants around the world to 5 by 2006. And in the first year, year and a half or so, it is more than investment as we spend the money to upgrade the plants that are seeing in the system and train the people, as well as the cost of transferring all of these products. But we are very pleased to see that the lean Six Sigma activities are getting us some early benefits which are ameliorating some of those costs.

    一般來說,回應你,Michael,當然你記得,我們正把全球 17 座工廠在 2006 年前縮減到 5 座。在第一年到一年半左右,更多是投資:我們投入資金升級將保留在體系內的工廠並訓練人員,還有移轉所有這些產品的成本。但我們很高興看到精實六標準差活動帶來一些早期效益,正在緩解其中一部分成本。

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • Michael, this is Bary. I wanted to get back to you. I apologize -- I realize what you're looking at. You're looking at the change year-over-year on the translation line, and I was focused on what impacted this first quarter. They are two very different items. Last year was -- the loss was due -- I mean a $4 million dollar credit was due to foreign currency translation. And as I mentioned last year, that is literally the shift over to accumulated translation on the balance sheet. There's largely no economic impact from that item. This year, there was not much change due to foreign currency translation, but it was absolutely impacted by us getting out of the investments. On a net cash basis, though, there was no impact for getting out of those investments.

    Michael,我是 Bary。我想再回到你剛才的問題。我很抱歉——我現在明白你在看什麼了。你是在看「換算」那一行的年度同比變動,而我剛才聚焦的是影響本季第一季的因素。那是兩個非常不同的項目。去年——該項的損失是因為——我是說,4 百萬美元的貸方(credit)是由外幣換算造成的。而如我去年提到的,那基本上就是轉入資產負債表上的累積換算調整(accumulated translation)。那一項在經濟實質上幾乎沒有影響。今年,外幣換算造成的變動不大,但確實受到我們退出那些投資的影響。不過以淨現金基礎來看,退出那些投資並沒有影響。

  • Michael Sansky - Analyst

    Michael Sansky - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Larry Smith, DLS Research.

    Larry Smith,DLS Research。

  • Larry Smith - Analyst

    Larry Smith - Analyst

  • Schering has just announced that they filed for Peg (ph) and Ribavirin in combination in Japan. Could you give us an idea of when you think they might gain approval? And second of all, could you frame the Japanese up to the -- relative to the U.S. and relative to Europe? There seems to be a lot of warehousing going on in Japan in anticipation of the launch of Peg and Ribavirin?

    Schering 剛宣布他們已在日本申請 Peg(音)與 Ribavirin 的合併療法。你能否給我們一個概念,你認為他們可能何時獲得核准?第二,你能否把日本市場相對於美國、相對於歐洲做個定位/比較?看起來日本在 Peg 與 Ribavirin 上市前,似乎有很多囤貨(warehousing)行為?

  • Timothy Tyson - Co-President, COO

    Timothy Tyson - Co-President, COO

  • Larry, thank you for the question. The information that we have is the same that you have. We have heard through different sources and from sharing that they expect somewhere in the October-November timeframe for approval in Japan. And the impact in Japan, you would have to estimate that and model it like us. We don't really have any more information about what may or may not happen. There appears to be some under treatment in Japan and better therapies usually indicate and drive additional revenue and sales. So there is some expectation there. And there are a lot of patients around the world in studies right now. And we believe that there's going to continue to be some marginal growth in the worldwide business, offset by some of the pricing pressures.

    Larry,謝謝你的問題。我們掌握的資訊和你一樣。我們從不同來源以及與 Schering 的交流中聽到,他們預期在 10 月到 11 月左右的時間窗口在日本獲得核准。至於日本的影響,你得像我們一樣去估算並建模。我們確實沒有更多關於可能或不可能發生什麼的資訊。日本似乎存在治療不足的情況,而更好的療法通常會帶動額外的營收與銷售。因此市場上有一些期待。而目前全球也有許多病患正在研究中。我們相信全球業務仍會有一些邊際成長,但會被部分定價壓力所抵銷。

  • Larry Smith - Analyst

    Larry Smith - Analyst

  • When do you anticipate -- is Roche on the same track as Schering? And did I hear you right that you're anticipating an October to November launch?

    您預期何時——羅氏(Roche)是否與先靈(Schering)在同樣的進度上?另外,我是否聽對了,您預期會在10月至11月上市?

  • Timothy Tyson - Co-President, COO

    Timothy Tyson - Co-President, COO

  • If you want to know the time they will be in the market, you should ask them. All I'm telling you is what they have told the market publicly is October, November from what we have seen in the data. But we are not sure what the approval time is.

    如果您想知道他們何時會進入市場,您應該去問他們。我能告訴您的只是,他們公開對市場所說的是10月、11月——就我們從數據中看到的情況而言。但我們不確定核准時間會是什麼時候。

  • Larry Smith - Analyst

    Larry Smith - Analyst

  • And Roche, do you know what kind of a timeframe Roche is on in Japan?

    那羅氏方面,您知道羅氏在日本的時程大概是怎樣嗎?

  • Timothy Tyson - Co-President, COO

    Timothy Tyson - Co-President, COO

  • I don't know what timeframe they are on. They are delayed, I know that.

    我不知道他們的時程。我知道的是,他們有延遲。

  • Larry Smith - Analyst

    Larry Smith - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Rachel Golder, Goldman, Sachs Asset Management.

    Rachel Golder,高盛資產管理(Goldman, Sachs Asset Management)。

  • Rachel Golder - Analyst

    Rachel Golder - Analyst

  • Thank you, I forgot to ask this the first time around. Are you still on track for redeeming your 6.5 percent converts this summer? And secondly, is there any - since I'm a bondholder, I will say -- risk of you doing any shareholder favorable activities, as in share repurchases in the near-term?

    謝謝,我第一次提問時忘了問這個。你們今年夏天仍按計畫贖回6.5%的可轉債嗎?第二,因為我是債券持有人,我想問——你們近期是否有任何偏向股東的活動風險,例如回購股票?

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • Rachel, we're absolutely on track for that redemption, and I will let Bary elaborate.

    Rachel,我們絕對按計畫進行該項贖回,我讓Bary再補充說明。

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • Rachel, relative to the last part of your question, obviously, we could not comment positively or negatively on any other issues. But no, we are absolutely on track relative to the buyback, the redemption of the 6.5. It's in July.

    Rachel,關於您問題的最後一部分,顯然我們無法對任何其他事項作出正面或負面的評論。但就回購、6.5%債券的贖回而言,是的,我們絕對按計畫進行。是在7月。

  • Rachel Golder - Analyst

    Rachel Golder - Analyst

  • And will that just be out of cash on hand? Do you have a huge cash balance?

    那會完全用手上現金來支付嗎?你們有很大的現金餘額嗎?

  • Bary Bailey - CFO, EVP

    Bary Bailey - CFO, EVP

  • Yes. As we originally intended, when we did the refinancing, we're going to use that cash to buy it back.

    是的。如同我們當初在再融資時的規劃,我們會用那筆現金把它買回來。

  • Rachel Golder - Analyst

    Rachel Golder - Analyst

  • And maybe a different way of asking my second question is, perhaps since you've emphasized you are focused on the long-term possibility of the Company is it fair to say that you're somewhat less sensitive to quarter-to-quarter swings in your share price that may reflect the quarter-to-quarter swings in your performance?

    或許換個方式問我第二個問題:既然你們強調專注於公司長期的可能性,是否可以說你們對股價逐季波動(可能反映你們業績逐季波動)相對沒那麼敏感?

  • Timothy Tyson - Co-President, COO

    Timothy Tyson - Co-President, COO

  • I think as we've been consistent, going back to when the management team first got here, our focus is on the long-term. We're going to continue to do that and to grow that business. That's where we're going to be and not quarter to quarter.

    我想我們一直都很一致,從管理團隊剛到任時就如此,我們的重點在長期。我們會持續這麼做並擴大那項業務。我們會把重心放在那裡,而不是一季一季地看。

  • Rachel Golder - Analyst

    Rachel Golder - Analyst

  • Thank you.

    謝謝。

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • Rachel, I couldn't have said it better myself. That is exactly our perspective. Yes, next question, please.

    Rachel,我自己也說不出更好的說法了。那正是我們的觀點。好的,請下一個問題。

  • Operator

    Operator

  • At this time, there are no further questions.

    目前沒有其他問題。

  • Robert O'Leary - Chairman, CEO

    Robert O'Leary - Chairman, CEO

  • If there are no more questions, then I promised you a brief comment on corporate governance and our CEO succession planning. Let me thank you first for your questions.

    如果沒有更多問題,那我先前承諾會就公司治理與我們的執行長接班規劃做一段簡短說明。首先感謝各位的提問。

  • I want to take just a moment before we close to bring you up-to-date on our progress in the area of corporate governance in general, and in particular, our progress against our CEO's succession plan. Among other governance initiatives, we have placed great emphasis, in addition to the emphasis on the CEO's succession plan, on the implementation of a formal and rigorous CEO evaluation process and on the implementation of our multi-year board assessment work plan in a robust nominating process which has seen the Company turn over 80 percent of the remaining board members in the last 22 months since the 2002 change of control.

    在結束之前,我想花一點時間向各位更新我們在公司治理整體方面的進展,特別是我們在執行長接班計畫上的進度。在其他治理措施中,除了對執行長接班計畫的重視之外,我們也非常強調導入正式且嚴謹的執行長評估流程,以及在健全的提名程序下推動我們為期多年的董事會評估工作計畫;自2002年控制權變更以來的22個月內,該提名程序已使公司更換了剩餘董事會成員中的80%。

  • As we first reported to you almost a year ago, the Board has engaged in a very deliberate and careful CEO succession planning process that's consistent with the current thinking in most governance circles today, provides that we will split the dual role of Chairman and CEO sometime next year. That plan is progressing well and on schedule. Accordingly, the Company has nominated Mr. Tyson for election to the Board of Directors at the annual meeting this year in order to position him to succeed to the role of Chief Executive Officer at the appropriate time.

    正如我們近一年前首次向各位報告的,董事會已展開一項非常審慎且周延的執行長接班規劃流程,該流程符合當今多數治理圈的主流思維,並規劃我們將在明年某個時間點拆分董事長與執行長的雙重職務。該計畫進展良好且按期推進。因此,公司已提名Tyson先生在今年的年度股東大會上競選董事,以便讓他在適當時機接任執行長一職。

  • In addition to these substantive governance improvements, we have of course complied early or as required with all of the new standards established by the SEC and the New York Stock Exchange. We on the Valeant Board share a commitment for moving beyond mere compliance and are dedicated to transparency and the continuous improvement in our governance practices and processes. Ladies and gentlemen, I want to thank you for your attention and your continued support and I wish you a good day.

    除上述實質性的治理改善外,我們當然也已提前或依規定遵循美國證券交易委員會(SEC)與紐約證券交易所所制定的所有新標準。我們Valeant董事會共同承諾不僅止於合規,並致力於透明化以及持續改善我們的治理實務與流程。各位女士、先生,感謝各位的關注與持續支持,祝各位有美好的一天。

  • Operator

    Operator

  • This concludes today's call. Thank you for your participation.

    今天的電話會議到此結束。感謝各位的參與。